The Latest News
We are pleased to announce that Professor Das Narayandas, BTech, PGDM, PhD, has joined the Advisory Board of Tullis Health Investors. Das Narayandas is the James J. Hill Professor of Business Administration at the Harvard Business School. He is currently the Senior Associate Dean, Chair, Harvard Business Publishing, and Senior Associate Dean, Chair, Executive Education.
The Tullis Growth Fund has completed its second investment into Orthosensor, a Florida-based maker of knee and joint implant placement technologies.
Valeritas, Inc., a leader in simple, disposable basal-bolus insulin delivery technology designed for patients with Type 2 diabetes, announced today that it has received a 2014 Cardinal Health Supply Chain Excellence Award. The award was presented October 16th at Cardinal's annual Business Partners Conference in Columbus, Ohio.
Synageva BioPharma Corp. ("Synageva") (GEVA), a biopharmaceutical company developing therapeutic products for rare disorders announced today the appointment of Robert Bazemore as Chief Operating Officer. Reporting directly to Sanj K. Patel, President and Chief Executive Officer, Robert will oversee the planned global commercial launch of the company's lead program, sebelipase alfa for LAL Deficiency, and will have responsibility for the company's global commercial, market access and medical affairs operations.
Exagen Diagnostics Inc. has filed its S-1 form with the U.S. Securities and Exchange Commission (SEC) for an initial public offering (IPO). No terms were given for the offering, but it has the potential to raise up to $69 million. The company plans to list on the Nasdaq Global Market under the symbol of EXDX. The underwriters for this initial offering are Leerink Partners, William Blair and Baird.
ElectroCore’s funding is $10 million oversubscribed by all parties including Merck’s GHI fund to bring it to $50 million>
electroCore, the New Jersey based electroceutical company has announced that its successful funding initiative of $40 million, announced in April last year, has been oversubscribed by $10 million by all parties including Merck’s Global healthcare Innovation fund and private equity groups Easton Capital and Core Ventures. The final tranche of $15 million of the $40 million was optional but following discussions between the investors this was not only made compulsory but increased by $10 million to a total of $50 million.
Synageva BioPharma™ Highlights Data Presentations And Satellite Symposium At The European Atherosclerosis Society Congress>
Synageva BioPharma Corp. (Synageva) (GEVA), a biopharmaceutical company developing therapeutic products for rare diseases, today announced data presentations and a company-sponsored satellite symposium at the European Atherosclerosis Society (EAS) Congress being held May 31-June 3, 2014 in Madrid, Spain.
Interim Analysis Suggests that Delivery of Insulin via Valeritas' V-Go® Shows Promise in Improving Glycemic Control for Patients with Type 2 Diabetes Previously Taking Long-Acting Insulin>
Valeritas, makers of the V-Go® Disposable Insulin Delivery Device, announced interim analysis data from SIMPLE, a prospective observational study, today that suggest patients with Type 2 diabetes who switched to V-Go therapy from their previous baseline treatment of long-acting insulin with or without oral medications experienced significantly improved glycemic control and a reduction in total daily insulin dose. The interim results, part of a planned interim analysis performed as part of the twelve month study, were presented at the American Association of Clinical Endocrinologists (AACE) 23rd annual scientific and clinical congress.
Following a successful proof of concept assessment in patients with gastroparesis, a clinical trial is commencing to treat patients with two of the most common gastrointestinal (“GI”) complaints, Irritable Bowel Syndrome (“IBS”) and functional dyspepsia. The trial, which is being held at the Royal Free Hospital in London, is a double-blind, parallel, sham- controlled trial involving 80 patients, using electroCore’s non-invasive vagus nerve stimulation (nVNS) therapy. Results are expected in the first quarter of 2015.
SupplyPro, Inc., announced today the launch of SupplyScale, a flexible weight-based inventory management solution that can be seamlessly integrated into a new or existing SupplyPro system.
Craig Giangregorio, an award-winning customer service professional with extensive software and engineering experience, has joined SupplyPro, Inc., a leading provider of inventory management solutions in a wide range of industries.
SafeOp Surgical, Inc. (“SafeOp”) has received FDA clearance to market its Evoked Potential Assessment Device (EPAD™). The device is portable and intended for use in monitoring neurological status by recording somatosensory evoked potentials (SSEPs) or assessing the neuromuscular junction (NMJ).
LivHOME, Inc., one of the nation’s largest providers of professionally led at-home care for seniors, announced today that it has appointed Richard (Rick) Slager to its Board of Directors. Slager will focus on seeking new opportunities for LivHOME to grow and develop as it continues bringing top quality care to seniors living at home.
AtriCure, Inc. (ATRC), a leading Atrial Fibrillation medical device provider, today announced the completion of the previously announced acquisition of Endoscopic Technologies, Inc. d/b/a Estech (“Estech”).
Medical device manufacturer Vidacare Corporation of San Antonio, Texas has entered into a merger agreement to be acquired by Teleflex Incorporated (NYSE: TFX) for $262.5 million plus Vidacare's net cash.
SupplyPro announces the promotion of Stan Sigman to EVP, Chief Revenue Officer and the creation of a global Customer Relationship Management Department including the promotion of Cari Palmer to VP, Chief Customer Relationship Management Officer (CCRMO).
SYNAGEVA BIOPHARMA™ ANNOUNCES ONE YEAR OF TREATMENT DATA WITH SEBELIPASE ALFA IN LATE ONSET LAL DEFICIENCY>
Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), today reported 12-month results from an ongoing extension study with sebelipase alfa in adults with late onset Lysosomal Acid Lipase (LAL) Deficiency. The data will be presented today by Reena Sharma, M.D., Consultant, Adult Inherited Metabolic Diseases, Salford Royal Hospital, U.K., during an oral presentation at the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) annual meeting being held in London, U.K., May 8-11, 2013.
Vidacare Corporation Expands Sales Force by Nearly 30 Percent to Support International Commercialization>
Vidacare Corporation has increased its sales force by approximately 30 percent to support international commercialization of the company’s products directly through to the end user. The company has hired over 20 sales professionals to represent Vidacare product systems, including the EZ-IO Intraosseous Vascular Access System and the OnControl Bone Marrow and Bone Access Systems, in targeted international markets.